70岁及以上糖尿病患者的平均HbA1c、HbA1c变异性与死亡率:一项回顾性队列研究
该回顾性队列研究纳入英国587家初级保健机构数据库中54803例70岁及以上1型或2型糖尿病患者,分析平均HbA1c及HbA1c变异性与全因死亡率的关系。中位随访5年期间17680例死亡,总死亡率为每1000人年77例。死亡率风险与平均HbA1c呈J型分布,且随HbA1c变异性增加而显著升高。
要点
- 平均HbA1c过高或过低均与死亡率风险增加相关,呈J型分布
- HbA1c变异性评分>80-100者较0-20者死亡风险显著升高(女性HR 2.47,男性HR 2.21)
- 调整变异性后,仅HbA1c极高值(女性>9.5%,男性>9%)时风险显著增加
核心结论
- 低水平和高水平的血糖控制均与死亡率风险增加相关,变异性水平似乎也是重要因素,提示中间范围的稳定血糖水平与较低风险相关。
- 通过HbA1c随时间变化评估的血糖变异性可能是理解老年糖尿病患者死亡风险的重要因素。
研究设计与样本
- 5年回顾性队列研究,使用The Health Improvement Network数据库,包含英国587家初级保健机构的数据。
- 纳入70岁及以上1型或2型糖尿病患者,共54803例(女性28017例,男性26786例)。
- 观察期包括4年基线导入期(自2003年起)和5年随访期(2007年至2012年)。
- 主要暴露变量为平均HbA1c和时间HbA1c变异性,主要结局为全因死亡时间。
- 平均HbA1c评估三种模型:模型1为2003-06年基线平均HbA1c,模型2为整个随访期平均,模型3为每年更新的时变平均。
主要发现
- 观察期间17680例死亡(女性8614/28017[30.7%],男性9066/26786[33.8%])。
- 总死亡率为每1000人年77例(女性每1000人年73例,男性每1000人年80例)。
- 两性死亡率风险均呈J型分布,HbA1c>8%(64 mmol/mol)和<6%(42 mmol/mol)时显著增加,但模型1中男性HbA1c 8%(64 mmol/mol)至<8.5%(<69 mmol/mol)及模型1和3中两性分别评估HbA1c<6%(42 mmol/mol)时超额死亡风险不显著。
- 所有模型中死亡率随HbA1c变异性增加而显著升高(总体及两性)。
- 模型2中,变异性评分>80至100者与0至20者相比,女性调整HR为2.47(95%CI 2.08-2.93),男性为2.21(95%CI 1.87-2.61)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glycaemic targets for older people have been revised in recent years because of concern that more stringent targets are associated with increased mortality. We aimed to investigate the association between glycaemic control (mean HbA1c) and variability (variability of HbA1c over time) and mortality in older people with diabetes. METHODS: We did a 5-year retrospective cohort study using The Health Improvement Network database, which includes data from 587 UK primary care practices. We included patients of either sex who were aged 70 years and older with type 1 or type 2 diabetes. The primary outcome was time to all-cause mortality. Our primary exposure variables were mean HbA1c and variability of HbA1c over time. The observation included a 4-year run-in period (from 2003) as a baseline, with a 5-year follow-up (from 2007 to 2012). We assessed mean HbA1c in three models: a baseline mean HbA1c for 2003-06 (model 1), the mean across the whole follow-up period (model 2), and a time-varying yearly updated mean (model 3). A variability score (from 0 [low] to 100 [high]) was calculated on the basis of number of changes in HbA1c of 0·5% (5·5 mmol/mol) or more from 2003 to 2012 or to the point of mortality, based on changes in the annual mean as per each model with a minimum of six readings. FINDINGS: The cohort consisted of 54 803 people, of whom 17 680 (8614 [30·7%] of 28 017 women and 9066 [33·8%] of 26 786 men) died during the observation period. The overall mortality rate was 77 per 1000 person-years (73 per 1000 person-years for women and 80 per 1000 person-years for men). The data showed a J-shaped distribution for mortality risk in both sexes, with significant increases with HbA1c values greater than 8% (64 mmol/mol) and less than 6% (42 mmol/mol), although excess mortality risk was non-significant in model 1 for men at HbA1c values of 8% (64 mmol/mol) to less than 8·5% (<69 mmol/mol) and in models 1 and 3 for both sexes assessed individually at HbA1c values less than 6% (42 mmol/mol). Mortality increased substantially with increasing HbA1c variability in all models (overall and for both sexes). For the model 2 HbA1c measure, the adjusted hazard ratios comparing patients with a glycaemic variability score of more than 80 to 100 with those with a score of 0 to 20 were 2·47 (95% CI 2·08-2·93) for women and 2·21 (1·87-2·61) for men. Fitting the mean HbA1c models with the glycaemic variability score altered the risk distribution; this observation was most marked in the model 2 analysis, in which a significant increased risk was only apparent with HbA1c values greater than 9·5% (80 mmol/mol) in women and 9% (75 mmol/mol) in men. INTERPRETATION: Both low and high levels of glycaemic control were associated with an increased mortality risk, and the level of variability also seems to be an important factor, suggesting that a stable glycaemic level in the middle range is associated with lower risk. Glycaemic variability, as assessed by variability over time in HbA1c, might be an important factor in understanding mortality risk in older people with diabetes. FUNDING: King's College London and Diabetes Frail.
引用
- Forbes A, Murrells T, Mulnier H, et al. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018. PMID: 29674135. doi:10.1016/S2213-8587(18)30048-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。